Management of High Blood Pressure in Diabetes Mellitus: Lessons from The ADA Recommendation
|
|
- Jayson Preston
- 5 years ago
- Views:
Transcription
1 R E V I E W A R T I C L E Management of High Blood Pressure in Diabetes Mellitus: Lessons from The ADA Recommendation Sarwono Waspadji INTRODUCTION Type 2 Diabetes Mellitus (T2DM) is often associated with devastating diabetic complications: nephropathy, retinopathy, coronary artery disease, cerebrovascular disease, peripheral vascular disease, and neuropathy. Hypertension is a common co-morbidity in diabetes mellitus, therefore the consequences of high blood pressure on T2DM should be considered. Among diabetics, hypertension is very commonly found as part of the metabolic-cardiovascular syndrome (insulin resistance syndrome = cardio-metabolic syndrome), clustered together with microalbuminuria. Components of metabolic-cardiovascular syndrome can be found as follows: Central obesity Insulin resistance Low HDL-cholesterol levels High triglyceride levels Systolic hypertension Absent nocturnal drop in blood pressure Salt sensitivity Male sex Increased cardiovascular oxidative stress Impaired endothelial function Abnormal coagulation / fibrinolytic profiles Several studies showed that hypertension is really a bad companion of diabetes when they coexist. The occurrence of microalbuminuria, left ventricular hypertrophy, ECG signs of MCI, and prior history of overt cardiac events double in their coexistence. The risk of Jakarta Diabetes and Lipid Centre,Division of Endocrinology and Metabolism, Department of Medicine,School of Medicine, University of Indonesia, Jakarta the development of MCI, stroke/tia and LVH are higher among hypertensive males and hypertensive females as compared to their normal counterparts. The higher the blood pressure the higher the cardiovascular mortality rates. There are many studies trying to document and to prove the association between hypertension and diabetic vascular complications. Many of them give conflicting results. One of the valid and well-recognized prospective studies is the Appropriate Blood Pressure Control in Diabetes Mellitus (ABCD study), which give strong evidence as for the relationship between blood pressure and chronic complications of diabetes mellitus, as summarized below. In diabetic population, hypertension has a significant propensity for the development of chronic diabetic complications. Table 1. Appropriate Blood Pressure Control in Diabetes Relationship Between Hypertension (> 140/90) and Diabetic Vascular Complications OR 95 % CI P Diabetic Nephropathy Cardiovasc. Disease Diabetic Neuropathy NS Diabetic Retinopathy Peripheral Vascular Disease <.05 Left Ventricular Hypertrophy <.001 *Presented at Symposium II Holistic Approach in Cardiovascular Disease, Hotel Sahid Jakarta February 8 th 2003 Local Data-Jakarta We have performed a population study in Depok, suburban area in 2001, coordinated with the WHO and the Ministry of Health, Republic of Indonesia. Total respondents were 960. The prevalence of DM (over 25 years old), based on 2 hrs blood glucose after 75 gram glucose load of > 200 mg/dl were 13.6 %, among which 4.3 % were known diabetics. Using fasting blood glucose of > 126 mg/dl yielded the prevalence of 8.3 %. The prevalence of hypertension in the population was 514/960=53.5 %. Among diabetics the preva- 31
2 Sarwono Waspadji Acta Med Indones-Indones J Intern Med lence of hypertension is higher (76.4 %) as compared to the total population. Among the diabetics we found that the presence of hypertension give a higher percentage of abnormal lipid profile (Total cholesterol > 200 mg/dl, LDL-chol > 100 mg/dl, HDL-chol. < 35 mg/dl and triglyceride > 150 mg/dl of 87.3 %, 94.5 %, 4.5 % and 54.5 % respectively) as compared to the lipid profile among non hypertensive diabetic patients (Total cholesterol > 200 mg/dl, LDL-chol > 100 mg/dl, HDL-chol. < 35 mg/dl and triglyceride > 150 mg/dl of 67.6 %, 73.5 %, 8.8 % and 47.1 % respectively). The WHR among hypertensive diabetics was higher (25.2 %) than among non-hypertensive diabetics (18.8 %). The occurrence of abnormal ECG was also higher (41.1 % vs. 25 %) in the hypertensive diabetics. We also evaluate newly registered patients in CiptoMangunkusumo Hospital during the years 1992, 1993, 1997 and Altogether there were 4195 attendees. Many of them were lost to follow up when we conducted the evaluation. Only 147 patients could be evaluated. Hospital data also showed that the co-morbidity of hypertension among diabetics gives a higher tendency of dyslipidemia (57.5 % vs %). Diabetic nephropathy, retinopathy and coronary artery disease were also more frequently found among hypertensive diabetics as compared to non-hypertensive diabetics patients (18.5 vs %, 22.2 vs %, and 21.2 vs respectively). Co-morbidity of hypertension and diabetes also tends to contribute to more diabetic vascular complication(s) Hospital data, 5-10 years after the initial treatment, showed that the co-morbidity of hypertension among diabetics gives a lower total cholesterol level. Co-morbidity of hypertension and diabetes tends to end with more diabetic vascular complication(s) Acknowledging the role of high blood pressure in the development of diabetic vascular complications, scientist all over the world try to prove that lowering the blood pressure is really beneficial in preventing diabetic vascular complications and its progression. Studies to answer this question are conducted, among others as follows, with the different blood pressure target and different medication used. Most of them showed promising results of lowering blood pressure in the attempt to reduce the diabetic vascular complications. HOT study proved that lowering diastolic blood pressure to the level of < 85 mm Hg resulted in a 30% risk reduction of cardiovascular events. Table 2. Studies Comparing Blood Pressure Targets and Medication(s) Used Active Placebo Treatment SHEP (1996) 143 / / 72 (low dose diuretics) Syst-Eur (1997) 153 / / 82 HOT (1998) 140 / 81 (Target diast. < 80) UKPDS (1998) 144 / 82 (Target BP <150/85) Tight control 143 / 85 (dihydropyridine Ca antagonist) (Target diast. < 90) 154 / 87 (Captopril vs. Atenolol) (Target BP 180/105) Less tight control UKPDS In the UKPDS group, blood pressure lowering was similarly effective for captopril and atenolol based regimens in reducing the incidence of both microvascular and macrovascular diabetic complications. It is worth to note that in UKPDS, modest reduction in blood pressure (- 10 / 5) proved to have higher DM-related events prevention as compared to modest reduction of blood glucose. Table 3. UKPDS Study: Cardiovascular Events in Intensive Blood Glucose Control vs Tight Blood Pressure Control Intensive BG Control Hb A1c 7 % vs. 7.9 % Diabetes related end-point - 12 % (p =.30) Microvascular end-point - 25 % (p=.010) MI - 16 % (p=.052) Tight BP Control 144 / 82 vs. 154 / 87 Diabetes related end-point - 24 % (p=.005) Micro vascular end-point - 37 % (p=.009) MI - 28 % (p=.10) Heart Failure - 56 % (p=.004) Stroke - 44 % (p=.013) HOPE STUDY MICRO-HOPE STUDY HOPE study was a randomized double blind evaluation of ACE inhibitor in patients at high risk for vascular disease complications without clinically evident heart failure. This study compared antihypertensive Ramipril and Placebo. Among 9297 respondents, there were 3577 Diabetics enrolled in HOPE MICRO-HOPE In keeping with the findings of the major trial, the primary and secondary outcome of MICRO-HOPE study were recorded as follows: Primary outcome Myocardial infarction, stroke, cardiovascular death Significantly decrease (25 %, p<0.0004, 95 % CI %) Secondary outcome Total mortality, need for revascularization Significantly lower Significant reduction in progression to overt nephropathy (16 %, 95% CI 1-29 %) 32
3 Vol 36 Number 1 January-March 2004 Management of High Blood Pressure No difference in admission for unstable angina or heart failure. Non-significant trend toward less laser therapy for retinopathy. Less progression to ESRD. Conclusion derived from all the prominent studies showed that lowering blood pressure to a certain degree is beneficial to reduce the diabetic vascular complications. MICROALBUMINURIA Many studies have shown that microalbuminuria is an independent risk factor for the development of CVD and a predictor of cardiovascular mortality in diabetic populations. Microalbuminuria is associated with insulin resistance, central obesity, absence of nocturnal blood pressure drop. Microalbuminuria is part of metabolic-cardiovascular syndrome associated with hypertension and it is also associated with endothelial dysfunction and increased oxidative stress. The longer the presence of microalbuminuria the higher the cumulative incidence of end stage renal disease. Several studies proved the superiority of ACE inhibitors as compared to other antihypertensive agents in lowering the urinary protein and microalbumin levels. The newly developed ARBs also proved the ability to reduce the development of overt proteinuria among diabetics (e.g. IRMA 2 Study). The use of these drugs in the management of hypertension in diabetes is therefore strongly recommended especially when microalbuminuria / proteinuria has developed in diabetic patients. IDNT Pilot Study has proved that irbesartan has been found to be more beneficial in reducing the urine protein excretion and in improving the creatinine clearance as compared to amlodipine. Another study (Psaty et al.) stunned the hypertensive community by providing strong evidence albeit nondefinitive, that certain CCB when used as drug therapy for hypertension were associated with an increased risk of myocardial infarction. However the latest evidence (ALLHAT study) did not give a different clinically relevant outcome when Lisinopril, Amlodipine and Chlorthalidone were comparatively used in the treatment of hypertension. The numbers of patients who succeeded in achieving the target blood pressure of less then 140/90 were similar in the three groups, 61 %, 66 % and 68 % respectively. Chlorthalidone and amlodipine did not increase cardiovascular events and mortality. Eventhough Lisinopril has been found to increase the risk of stroke and combined cardiovascular disease among black respondents. Considering the fact that lowering blood pressure proved to be beneficial and that microalbuminuria also has an important role in the development and progression of chronic diabetic vascular complications, consensus on the threshold of starting to treat hypertensive patients and the selected blood pressure target level has been endorsed by a group of experts around the world. The authority therefore set up the threshold for treating hypertensive diabetics and also the target blood glucose level to prevent the diabetic vascular complications. Table 4. British Hypertension Society Threshold and Target BP Recommendation for Antihypertensive in Diabetes Mellitus Threshold BPs Systolic > 140 Or Diastolic > 90 Target (clinic) BPs Systolic < 140 And Diastolic < 90 Based on several guidelines, in 2002, the American Diabetes Association recommended the target BP in the treatment of DM as 130/85, with less ambitious goal for the elderly. Table 5. American Diabetes Association Recommendation for The Treatment of Hypertensionin Diabetes Mellitus Category Goal (mmhg) Initial Therapy All Non-pregnant Diabetics > 18 y.o Isolated SBP Isolated SBP > 180 < 130 / 80 Lifestyle : weight loss, exercise,reduced salt and alcohol Lower BP by 20 Then < 130 / 80 SBP < 160, Then < 130 / 80 Lifestyle Antihypertensive Lifestyle Antihypertensive As for the treatment, they recommended open choice for the initial treatment of hypertension in Diabetes Mellitus, using any class of drugs that is used in treatment of hypertension, and add another class of antihypertensive drugs for the second line treatment. The Indonesian Society of Endocrinology has convened already, during which algorithm on the threshold of hypertension that should be treated has been agreed upon together. The recommended algorithm in the management of hypertension in diabetes mellitus, which is based fully on ADA recommendation 2002 has been developed and distributed in the medical community in the PERKENI consensus on the management of Diabetes Mellitus 2002 as can be seen below. 33
4 Sarwono Waspadji Acta Med Indones-Indones J Intern Med Treatment Goal < 130/85 Initiate Pharmacologic Selection (in alphabetical order), Plus Lifestyle Modifications (ACE Inhib, Beta Blockers, Ca Antagonist, and Diuretics in low dose) ACE inhibitors are drugs of choice in patients with albuminuria/ proteinuria Table 6. The Indonesian Society of Endocrinology. Threshold and Target BP Recommendation for Antihypertensive in Diabetes Mellitus Threshold BPs Systolic > 130 or Diastolic > 80 Target (clinic) BPs Systolic < 130 and Diastolic< 80 With Proteinuria Systolic < 125 and Diastolic< 75 Isolated Systolic Hypertension: gradually,upto < 140 /90 Syst Syst. > 140 Diast. > 90 Diast Inadequate Response Lifestyle Modification 3 months, inadequate response Increase drug dose Add a second agent from a different class (e.g. diuretic, if not selected initially) Life-style + ACE Inhibitors Beta Blockers Diuretics 1-2 months, target not achieved AIIRA Increase Dose Change to other - antihypert. Add other antihypert. Inadequate Response Add other antihypertensive (second, third, etc., (one of them should be diuretics) Add a second or third, one of which should be diuretic, if not already prescribed Figure 1. Algorithm for Treatment of Hypertension in Diabetics (ADA Recommendation) The Indonesian Society of Endocrinology Threshold and target BP recommendation for antihypertensive in diabetes mellitus. If microalbuminuria, or macroalbuminuria clinical nephropathy present, use ACE inhibitors, or AIIRA or non dihydropyridine Ca antagonist. Extensive discussion on the choice of treatment is beyond the scope of this presentation. However some lessons from the ADA recommendation will be mentioned. Some evidence based recommendation from the ADA 2002 and 2003 were presented together to show that even a big and prominent international organization seem to hesitate and to be very thoughtful in making recommendations as for the treatment of hypertension in diabetes mellitus since there are a lot of controversies that much be raffled and settled together before we have better, stronger and widely accepted algorithm in the treatment of hypertension in diabetes mellitus. This can be seen from the changes in their recommendations in 2002 and Figure 2. Algorithm for Treatment of Hypertension in Diabetics (The Indonesian Endocrine Society Consensus 2002) ADA RECOMMENDATIONS 2002 Initial therapy: may be with ACE inhibitor, ARB, beta-blockers or diuretics In microalbuminuria or clinical albuminuria: ACE inhibitor or ARB In diabetics > 55 y.o. with or without hyperten sion but with risk factor(s): ACE inhibitor should be considered In diabetics with recents MCI: beta-blockers should be considered. When ACE inhibitor or ARB is not tolerated, consider non-dccb When using ACE inhibitor / ARB: monitor serum creatinine and potassium In the elderly, blood pressure should be lowered gradually Patients, which do not achieve target with 3 drugs and with severe renal disease, should be referred to specialist experienced in hypertension care. ADA RECOMMENDATIONS 2003 Initial treatment: may be any drug class currently used. ACE inhibitor, Beta Blockers, Diuretics are preferred agents. 34
5 Vol 36 Number 1 January-March 2004 Management of High Blood Pressure Others are similar to the ADA recommendation New evidence (the ALLHAT study) provides compelling evidence that thiazide diuretics should also be used as one of the initial drug of choice in the treatment of hypertension. CONCLUSION Hypertension is a common co-morbidity in diabetes mellitus, therefore the consequences of high blood pressure on T2DM should be considered. Hypertension and diabetes mellitus are often clustered together as a part of the metabolic-cardiovascular syndrome. Treating hypertension in diabetics should take into account all aspects of the patient s condition, metabolic-cardiovascular as well as socio-aconomic aspects, especially in the elderly, avoiding multipharmacy in managing multipathology. A logical strategy that incorporate low cost agents may differ from more popular contemporary strategy which may be somewhat influenced by marketing activities to using expensive medications. In fact physician have the means to effectively control blood pressure with inexpensive medications, even among patients who require multiple drugs. This issue should be stressed as physicians have to consider cost-effectiveness in patient management 10. American Diabetes Association. Standard of medical care for patients with diabetes mellitus. Clinical Diabetes 2002; 20(1); American Diabetes Association. Standard of medical care for patients with diabetes mellitus. Diabetes Care 2003; 26(1); S Pacheco CA, Parrot MA, Raskin P. The treatment of hypertension in adults patients with diabetes mellitus. Diabetes Care 2002; 25(1): Appel LJ. The verdict from ALLHAT- thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002; 288(23): Epstein M. Recent landmark clinical trials: How do they modify the therapeutic paradigm?. AJH 2002;15: 82S-4S. 15. Supartondo. Kecenderungan polifarmasi pada multipatologi: apa masalahnya. Penatalaksanaan pasien geriatri dengan pendekatan interdisiplin. Prosiding temu ilmiah geriatri Dalam: Supartondo, Siti Setiati, Czeresna H Soejono,eds. Jakarta: Pusat Informasi dan Penerbitan Bagian Ilmu Penyakit Dalam; 2003.p REFERENCES 1. Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanism of diabetic vasculopathy: an overview. AJH 2001;14: Diabetes Guidelines Work Group. Massachuset guidelines for adult diabetes care. Revised June Diabetes Control Program. Hypertension 3. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: Melers PS, Jeffers BW, Estacio R, Schrier RW. Association of hypertension and complications in non-insulin dependent diabetes mellitus. AJH 1997;10: Feher MD. Hypertension in diabetes. Pract Diab Int 2001; 18(6): Adler AI, Stratton IM, Neil HAW, etal. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: PB Perkeni. Konsensus pengelolaan diabetes melitus di indonesia. Jakarta, American Diabetes Association. Treatment of hypertension in adults with diabetes mellitus. Diabetes Care 2002; 25(1): American Diabetes Association. Treatment of hypertension in adults with diabetes mellitus. Diabetes Care 2003; 26(1): S
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationRandomized Design of ALLHAT BP Trial
Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* *Wright JT, Dunn JK, Cutler JA et al. JAMA 2005:293:1595-1608. 42,418 High-risk hypertensive
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status
ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationObjectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence
JNC 7 Is Nice But What s Up With JNC 8? 37 th Annual CAPA Conference October 4 th 2013 Ignacio de Artola, Jr. M.D. Assistant Professor of Clinical Family Medicine Medical Director, Primary Care Physician
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationBlood pressure treatment target in diabetes. Should it be <130 mmhg?
Blood pressure treatment target in diabetes Should it be
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationHypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?
Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationRATIONALE. chapter 4 & 2012 KDIGO
http://www.kidney-international.org chapter 4 & 2012 KDIGO Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus Kidney International Supplements (2012) 2, 363 369; doi:10.1038/kisup.2012.54
More informationManagement of Hypertension. Ahmed El Hawary MD Suez Canal University
Management of Hypertension Ahmed El Hawary MD Suez Canal University Minimal vs. Optimal Care Resources more than science affect type of care and level of management. what is possible (minimal care) and
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationRENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2
Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationDysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale
Dysglycaemia and Hypertension Dr E M Manuthu Physician Kitale None Disclosures DM is MI equivalent MR FIT Objective was to assess predictors of CVD mortality among men with and without diabetes and
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationDIABETES MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: DIABETES MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DIABETES MEASURES GROUP: #1. Diabetes: Hemoglobin A1c Poor Control #2. Diabetes: Low Density Lipoprotein (LDL-C)
More informationDiabetes Overview. How Food is Digested
Diabetes Overview You are The Teacher, The Coach and the Fan Pathophysiology of Diabetes Complications Know the Numbers Treatment Can Good Control Make a Difference? Can Tight Control Be too Tight? How
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More information2014 HYPERTENSION GUIDELINES
2014 HYPERTENSION GUIDELINES Eileen M. Twomey, Pharm.D., BCPS 1 Learning Objectives Describe specific blood pressure thresholds at which antihypertensive therapy should be initiated and blood pressure
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationTalking about blood pressure
Talking about blood pressure Mrs Khan 56 BP 158/99 BMI 32 Total cholesterol 5.4 (HDL 0.8) HbA1c 43 She has been promising to do more exercise and eat more healthily for the last 2 years but her weight
More informationHow Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
More informationHypertension is a major risk factor for
OPTIMAL RISK MANAGEMENT OF THE HYPERTENSIVE PATIENT WITH MULTIPLE RISK FACTORS * Keith C. Ferdinand, MD, FACC ABSTRACT To determine the risk of cardiovascular disease in patients with hypertension, it
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More informationABSTRACT CARDIOVASCULAR RISK MANAGEMENT
Management of Hypertension in Patients with Type 2 Diabetes Saman Nazarian, MD, and Roger S. Blumenthal, MD, FACC, FCCP ABSTRACT Type 2 diabetes is a common condition that accounts for significant morbidity
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationPre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.
Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationHypertension Management in Diabetic Patients
Hypertension Management in Diabetic Patients Park, Chang G, MD, PhD Cardiovascular Center, Guro Hospital, Korea University Medical School Contents (Treatment of 2 Cases) Type 2 Diabetes Mellitus Hypertension
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationALLHAT and its implications in the diabetic population
SPECIAL REPORT ALLHAT and its implications in the diabetic population Samy I McFarlane, MD, MPH, FACP Associate Professor of Medicine, Fellowship Program Director, Division of Endocrinology, Diabetes and
More informationNew Treatment Options for Diabetic Nephropathy patients. Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland
New Treatment Options for Diabetic Nephropathy patients Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland Diabetes and nephropathy Diabetic nephropathy is the most common
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationMPharmProgramme. Hypertension (HTN)
MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationManagement of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers. Robert D. Toto, MD
R e v i e w P a p e r Management of Hypertensive Chronic Kidney Disease: Role of Calcium Channel Blockers Robert D. Toto, MD Both the prevalence and incidence of end-stage renal disease have been increasing
More informationA Fork in the Road: Navigating Through New Terrain
A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationDiabetes Complications Guideline Based Screening, Management, and Referral
Diabetes Complications Guideline Based Screening, Management, and Referral Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine Assistant Medical Director Altru Diabetes
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationVALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION
VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationAbbreviations Cardiology I
Cardiology I and Clinical Controversies Joseph J. Saseen, Pharm.D., FCCP, BCPS (AQ Cardiology) Reviewed by Stuart T. Haines, Pharm.D., FCCP, BCPS; and Michelle M. Richardson, Pharm.D., FCCP, BCPS Learning
More informationAPPENDIX D: PHARMACOTYHERAPY EVIDENCE
Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991
More informationUpdate in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP
Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension
More information